You are viewing the site in preview mode

Skip to main content

Volume 7 Supplement 2

Basic science, rationale, background and future of abatacept

Reviews

Edited by Peter E Lipsky and Ravinder N Maini

Supported by an educational grant from Bristol-Myers Squibb Company

  1. Rheumatoid arthritis (RA) is a common destructive inflammatory disease that affects 0.5–1% of the population in many countries. Even though several new treatments have been introduced for patients with RA, a c...

    Authors: Vivianne Malmström, Christina Trollmo and Lars Klareskog
    Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S15
    Content type: Review Published on:

  2. Abatacept (CTLA4–Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28–CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficac...

    Authors: Eric M Ruderman and Richard M Pope
    Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S21
    Content type: Review Published on:

  3. T cells, in particular CD4+ T cells, have been implicated in mediating many aspects of autoimmune inflammation. However, current evidence suggests that the role played by CD4+ T cells in the development of rheuma...

    Authors: Alla Skapenko, Jan Leipe, Peter E Lipsky and Hendrik Schulze-Koops
    Citation: Arthritis Research & Therapy 2005 7(Suppl 2):S4
    Content type: Review Published on:
  • Logo
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 4.4
    5-year Journal Impact Factor: 4.9
    Source Normalized Impact per Paper (SNIP): 1.294
    SCImago Journal Rank (SJR): 1.518

    Speed 2024
    Submission to first editorial decision (median days): 11
    Submission to acceptance (median days): 118

    Usage 2024
    Downloads: 3,978,337
    Altmetric mentions: 1,452

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us